News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
735,659 Results
Type
Article (41937)
Company Profile (274)
Press Release (693434)
Multimedia
Podcasts (101)
Webinars (20)
Section
Business (205486)
Career Advice (2037)
Deals (35699)
Drug Delivery (134)
Drug Development (81862)
Employer Resources (173)
FDA (16547)
Job Trends (15055)
News (347876)
Policy (32790)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2631)
Academic (1)
Accelerated approval (56)
ADA (44)
Adcomms (28)
Allergies (200)
Alliances (49760)
ALS (221)
Alzheimer's disease (1826)
Antibody-drug conjugate (ADC) (502)
Approvals (16991)
Artificial intelligence (714)
ASCO (329)
Autoimmune disease (337)
Automation (58)
Bankruptcy (362)
Best Places to Work (11692)
BIOSECURE Act (20)
Biosimilars (234)
Biotechnology (177)
Bladder cancer (200)
Brain cancer (74)
Breast cancer (789)
Cancer (6218)
Cardiovascular disease (499)
Career advice (1732)
Career pathing (44)
CAR-T (353)
CDC (58)
Celiac Disease (3)
Cell therapy (947)
Cervical cancer (53)
Clinical research (71551)
Collaboration (2180)
Commercialization (1)
Company closure (5)
Compensation (1474)
Complete response letters (83)
COVID-19 (2771)
CRISPR (114)
C-suite (1213)
Cystic fibrosis (155)
Data (8534)
Decentralized trials (3)
Denatured (33)
Depression (170)
Dermatology (96)
Diabetes (656)
Diagnostics (7019)
Digital health (63)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (350)
Drug pricing (203)
Drug shortages (31)
Duchenne muscular dystrophy (296)
Earnings (92318)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (120882)
Executive appointments (1113)
FDA (20462)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (35)
Funding (1820)
Gene editing (241)
Generative AI (60)
Gene therapy (743)
GLP-1 (1087)
Government (4755)
Grass and pollen (8)
Guidances (415)
Healthcare (19224)
Hematology (193)
HIV (88)
Huntington's disease (59)
IgA nephropathy (110)
Immunology and inflammation (324)
Immuno-oncology (101)
Indications (209)
Infectious disease (3135)
Inflammatory bowel disease (224)
Inflation Reduction Act (16)
Influenza (140)
Intellectual property (312)
Interviews (321)
IPO (16703)
IRA (52)
Job creations (3661)
Job search strategy (1433)
JPM (59)
Kidney cancer (20)
Labor market (109)
Layoffs (576)
Leadership (41)
Legal (7955)
Liver cancer (103)
Longevity (34)
Lung cancer (823)
Lymphoma (467)
Machine learning (63)
Management (59)
Manufacturing (1120)
Marketing (1)
MASH (205)
Medical affairs (1)
Medical device (13980)
Medtech (14135)
Mergers & acquisitions (20283)
Metabolic disorders (1627)
mRNA (226)
Multiple sclerosis (196)
NASH (17)
Neurodegenerative disease (447)
Neuropsychiatric disorders (110)
Neuroscience (3427)
Neurotech (1)
NextGen: Class of 2026 (6540)
Non-profit (4551)
Now hiring (79)
Obesity (751)
Opinion (291)
Ovarian cancer (237)
Pain (263)
Pancreatic cancer (338)
Parkinson's disease (384)
Partnered (34)
Patents (626)
Patient recruitment (733)
Peanut (68)
People (60054)
Pharmaceutical (61)
Pharmacy benefit managers (33)
Phase 1 (22335)
Phase 2 (31529)
Phase 3 (23438)
Pipeline (9575)
Policy (329)
Postmarket research (2573)
Preclinical (9522)
Press Release (66)
Prostate cancer (332)
Psychedelics (55)
Radiopharmaceuticals (341)
Rare diseases (1143)
Real estate (5995)
Recruiting (70)
Regulatory (25712)
Reports (56)
Research institute (2434)
Resumes & cover letters (354)
Rett syndrome (42)
RNA editing (25)
RSV (89)
Schizophrenia (184)
Series A (310)
Series B (225)
Service/supplier (11)
Sickle cell disease (119)
Special edition (24)
Spinal muscular atrophy (167)
Sponsored (49)
Startups (3670)
State (2)
Stomach cancer (18)
Supply chain (133)
Tariffs (87)
The Weekly (66)
Vaccines (1147)
Venture capital (119)
Weight loss (481)
Women's health (134)
Worklife (20)
Date
Today (105)
Last 7 days (516)
Last 30 days (2835)
Last 365 days (30566)
2026 (15360)
2025 (30309)
2024 (35350)
2023 (40210)
2022 (51334)
2021 (55866)
2020 (54237)
2019 (46646)
2018 (35124)
2017 (32206)
2016 (31569)
2015 (37634)
2014 (31385)
2013 (26428)
2012 (28651)
2011 (29330)
2010 (27397)
Location
Africa (744)
Alabama (98)
Alaska (7)
Arizona (363)
Arkansas (14)
Asia (40097)
Australia (6586)
California (13874)
Canada (3904)
China (1474)
Colorado (594)
Connecticut (608)
Delaware (430)
Europe (86977)
Florida (2074)
Georgia (442)
Hawaii (3)
Idaho (63)
Illinois (1140)
India (96)
Indiana (625)
Iowa (24)
Japan (580)
Kansas (134)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1655)
Massachusetts (9963)
Michigan (374)
Minnesota (749)
Mississippi (6)
Missouri (147)
Montana (34)
Nebraska (30)
Nevada (147)
New Hampshire (84)
New Jersey (3631)
New Mexico (31)
New York (3626)
North Carolina (1747)
North Dakota (9)
Northern California (7005)
Ohio (414)
Oklahoma (23)
Oregon (41)
Pennsylvania (2758)
Puerto Rico (30)
Rhode Island (52)
South America (1114)
South Carolina (86)
South Dakota (2)
Southern California (5486)
Tennessee (222)
Texas (2214)
United States (48939)
Utah (411)
Vermont (1)
Virginia (344)
Washington D.C. (81)
Washington State (1107)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
735,659 Results for "triumvira immunologics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.
May 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium
January 27, 2025
·
2 min read
Press Releases
Triumvira Immunologics to Present Updated Clinical Data at the 2025 SITC Spring Scientific, Cellular Therapy and Solid Tumors Conference
March 12, 2025
·
3 min read
Deals
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
BioSpace and guests from Halia Therapeutics, Triumvira Immunologics and the Alzheimer’s Drug Discovery Foundation discuss alternative financing strategies to consider for 2024. Listen now.
January 4, 2024
·
1 min read
·
BioSpace Insights
Triumvira Immunologics to Present Clinical Data at the 2024 ASCO Gastrointestinal Cancers Symposium
Triumvira Immunologics today announced that it will present two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, California, from January 18-20, 2024.
December 19, 2023
·
3 min read
Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting
Triumvira Immunologics today announced that it will participate with one oral presentation and four posters at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, from November 1-5.
October 30, 2023
·
4 min read
Approvals
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
March 18, 2026
·
3 min read
·
Annalee Armstrong
Business
Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives
Triumvira Immunologics today announced the strengthening of its leadership team with the appointments of Mr. Robert Williamson as President, Chief Operating Officer and member of the Board of Directors, Mr. Jeffrey Erickson as VP of Business Development, and Mr. Chris Murray as VP of Human Resources.
July 20, 2023
·
4 min read
Press Releases
Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline
April 28, 2026
·
3 min read
Drug Development
Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors
Triumvira Immunologics today announced that the first patient has been dosed in its TACTIC-3 trial, a Phase I/II study, (NCT05862324) investigating the safety and efficacy of autologous TAC-T cell asset, TAC101-CLDN18.2, targeting Claudin 18.2+ solid tumors.
February 5, 2024
·
3 min read
1 of 73,566
Next
